Nuvalent Inc (NUVL) vs Teladoc Health, Inc. (TDOC)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NUVL | TDOC | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Health Information Services |
| Size band | MID | SMALL |
| Listing | Nasdaq GM | NYSE |
| Country | United States | United States |
| Theme | oncology | telemedicine |
| Price and returns | ||
| Last close | $123.96 | $6.24 |
| Return · 1 week | 0.00% | +8.90% |
| Return · 1 month | 0.00% | +5.94% |
| Return · 3 months | 0.00% | −33.33% |
| Return · year to date | +22.93% | −11.49% |
| Return · 1 year | +26.87% | −30.74% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −0.02% | −36.89% |
| 52-week high | $123.99 | $9.89 |
| 52-week low | $87.30 | $4.40 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $9.79B | $1.15B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $149.69M | $21.43M |
| Employees | 234 | 4,648 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | — | 0.42× |
| Price to book | 8.33× | 0.80× |
| Enterprise value to EBITDA | — | 19.70× |
| Enterprise value to revenue | — | 0.51× |
| Earnings per share · trailing | -6.06 | -1.03 |
| Profitability | ||
| Gross margin | — | 68.97% |
| Operating margin | 0.00% | −5.68% |
| Profit margin | — | −7.13% |
| Return on equity | −41.19% | −12.99% |
| Return on assets | −22.51% | −3.22% |
| Growth | ||
| Revenue growth | — | −4.00% |
| Balance sheet and payout | ||
| Debt / equity (%) | — | 79.09 |
| Current ratio | 16.14 | 0.83 |
| Dividend yield | — | 0.00% |
| Payout ratio | 0.00% | — |
| Trend and volatility | ||
| RSI · 14 | — | 57.63 |
| ADX · 14 | — | 17.28 |
| 50-day average | — | $6.16 |
| 200-day average | — | $6.47 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | — | 4.07% |
The full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysisThe full TDOC analysis
Everything this table leaves out for Teladoc Health, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TDOC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TDOC analysis